ENTA vs. AUTL, STOK, URGN, PHAT, RLAY, ABUS, TNGX, CDXC, DNTH, and MENS
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), Dianthus Therapeutics (DNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs. Its Competitors
Enanta Pharmaceuticals (NASDAQ:ENTA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Enanta Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Autolus Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Autolus Therapeutics' return on equity of -52.82% beat Enanta Pharmaceuticals' return on equity.
In the previous week, Autolus Therapeutics had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 5 mentions for Autolus Therapeutics and 2 mentions for Enanta Pharmaceuticals. Autolus Therapeutics' average media sentiment score of 0.71 beat Enanta Pharmaceuticals' score of 0.62 indicating that Autolus Therapeutics is being referred to more favorably in the news media.
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Enanta Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
Enanta Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 148.96%. Autolus Therapeutics has a consensus price target of $9.32, suggesting a potential upside of 285.12%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Enanta Pharmaceuticals.
Summary
Autolus Therapeutics beats Enanta Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 7/17/2025 by MarketBeat.com Staff
Free ENTA Stock Alerts